Namely, a group including BC, CNS, genitourinary/prostate (GU),and gynecological malignancies (80% PD-L1+) and a group including gastrointestinal (GI), liver, pancreatic, biliary tract, pulmonary, pleural, H&N, skin, and rare tumors (61% PD-L1+). This evidence concerns the gene CD274 and breast cancer.